RxDoctor Payments Data

Lin Chang, MD

Gastroenterology · Los Angeles, CANPI 1770518557

Payments from drug & device makers

$146,654in general payments, 2019–2025

Across 71 payments — averaging $2065.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Anx Robotica Corp$48K
  • Ironwood Pharmaceuticals, Inc$31K
  • Shire North American Group Inc$13K
  • Alnylam Pharmaceuticals Inc.$13K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$10K
  • GSK$8K
  • plus $24K from 12 others
$7,500in research payments, 2019–2025

Across 1 payment — averaging $7500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ardelyx, Inc.$8K

What the payments were for

  • Consulting fees$72,05791%
  • Speaking & faculty fees$2,4263%
  • Travel & lodging$1,1411%
  • Food & beverage$3,5675%
  • Education$40%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$146,654 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$19,852
Medicare patients
67
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide67$49,015
MotegrityPrucalopride Succinate54$29,087
ViberziEluxadoline16$15,274
SavellaMilnacipran Hcl12$5,405
Lubiprostone21$2,240
Desipramine Hcl13$1,241
Nortriptyline Hcl31$598
Ondansetron OdtOndansetron20$566
Oxycodone Hcl13$348
Venlafaxine Hcl ErVenlafaxine Hcl16$272
Pregabalin16$172
Quetiapine Fumarate11$92
Zolpidem Tartrate12$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Viberzi, Savella$6,655$69,69395 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,540$29,08754 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →